Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies

被引:252
作者
Gao, Yu [1 ]
Tan, Lin [1 ,2 ]
Yu, Jin-Tai [1 ]
Tan, Lan [1 ]
机构
[1] Qingdao Univ, Qingdao Municipal Hosp, Sch Med, Dept Neurol, Qingdao, Peoples R China
[2] Ocean Univ China, Coll Med & Pharmaceut, Qingdao, Peoples R China
基金
中国国家自然科学基金;
关键词
Tau; aggregation; phosphorylation; NFTs; Alzheimer's disease; therapy; AGGREGATION INHIBITOR THERAPY; DIET-INDUCED OBESITY; PATHOLOGICAL TAU; MOUSE MODEL; PHOSPHORYLATED TAU; AMYLOID-BETA; IN-VITRO; A-BETA; PROMOTES NEURODEGENERATION; CEREBROSPINAL-FLUID;
D O I
10.2174/1567205014666170417111859
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Alzheimer's disease (AD), the most important progressive neurodegenerative disorder, is characterized by cognitive and behavioral disabilities. Nowadays, tau, as a microtubule-associated protein and a principle neuropathological hallmark of AD, provides us a neoteric perspective to explore further aetiopathogenesis and therapeutic strategy. The hyperphosphorylation and abnormal aggregation of tau, combined with its decreased clearance, form neurofibrillary tangles (NFTs) and exert neurotoxicity in AD. Methods: Recent investigations aim to prevent the deposition of NFT and accelerate the clearance of NFT. Intriguingly, immunization strategies targeting tau effectively ameliorates the tau-associated pathology in AD. In addition, modified therapies targeting tau should be regarded as a potential way to treat AD. These progresses open new avenues for AD. Conclusion: Here, we review the recent literature of potential mechanisms of the tau in AD and discuss the modified therapeutic strategies for AD.
引用
收藏
页码:283 / 300
页数:18
相关论文
共 183 条
[91]  
Lee G, 1998, J CELL SCI, V111, P3167
[92]   Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system [J].
Lee, Min Jae ;
Lee, Jung Hoon ;
Rubinsztein, David C. .
PROGRESS IN NEUROBIOLOGY, 2013, 105 :49-59
[93]   Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease [J].
Lefebvre, Tony ;
Dehennaut, Vanessa ;
Guinez, Celine ;
Olivier, Stephanie ;
Drougat, Ludivin ;
Mir, Anne-Marie ;
Mortuaire, Marlene ;
Vercoutter-Edouart, Anne-Sophie ;
Michalski, Jean-Claude .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2010, 1800 (02) :67-79
[94]   BAG3 facilitates the clearance of endogenous tau in primary neurons [J].
Lei, Zhinian ;
Brizzee, Corey ;
Johnson, Gail V. W. .
NEUROBIOLOGY OF AGING, 2015, 36 (01) :241-248
[95]   Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies [J].
Lewis, Jada ;
Dickson, Dennis W. .
ACTA NEUROPATHOLOGICA, 2016, 131 (01) :27-48
[96]  
Li Ge, 2013, IUBMB Life, DOI [10.1002/iub.1165, 10.1002/iub.01165]
[97]   Ionizing radiation causes increased tau phosphorylation in primary neurons [J].
Li, Li ;
Wang, Wenzhang ;
Welford, Scott ;
Zhang, Teng ;
Wang, Xinglong ;
Zhu, Xiongwei .
JOURNAL OF NEUROCHEMISTRY, 2014, 131 (01) :86-93
[98]   Tau acts as a mediator for Alzheimer's disease-related synaptic deficits [J].
Liao, Dezhi ;
Miller, Eric C. ;
Teravskis, Peter J. .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2014, 39 (07) :1202-1213
[99]   The Eye As a Biomarker for Alzheimer's Disease [J].
Lim, Jeremiah K. H. ;
Li, Qiao-Xin ;
He, Zheng ;
Vingrys, Algis J. ;
Wong, Vickie H. Y. ;
Currier, Nicolas ;
Mullen, Jamie ;
Bui, Bang V. ;
Nguyen, Christine T. O. .
FRONTIERS IN NEUROSCIENCE, 2016, 10
[100]   How it all Started: Tau and Protein Phosphatase 2A [J].
Liu, Chang ;
Goetz, Juergen .
JOURNAL OF ALZHEIMERS DISEASE, 2013, 37 (03) :483-494